Filing Flows › Metagenomi Therapeutics (MGX) › Q4 2024
Metagenomi Therapeutics (MGX) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 17, 2025
Metagenomi Therapeutics (MGX) reported revenue of $9.6M for the fourth quarter 2024 (Q4 2024), -22% from a year earlier and -17% from the quarter before. Operating margin was -214.5%, net loss $23.4M (243.4% of revenue).
Metagenomi Therapeutics, Q4 2024: revenue $9.6M (-22% year over year), operating margin -214.5%, net loss $23.4M, operating cash flow −$26.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.6M | -17% | -22% |
| Operating profit | −$20.6M | — | — |
| Net earnings | −$23.4M | — | — |
| Operating cash flow | −$26.3M | — | — |
What changed
Revenue was $9.6M in Q4 2024, down 22% year over year and down 17% from the previous quarter.
Operating costs exceeded revenue by $20.6M, an operating margin of -214.5%. Total costs fell 7% while revenue fell 22%. The quarter ended with a net loss of $23.4M, wider than the previous quarter's $18.8M loss.
Operating cash flow was −$26.3M. Non-cash charges added back $1.5M of depreciation and $3.4M of share-based compensation. Working capital and other items used $7.8M. Capital expenditures of $334K exceeded it, leaving free cash flow of −$26.6M.
Questions
What was Metagenomi Therapeutics' revenue in the fourth quarter 2024?
Metagenomi Therapeutics (MGX) reported revenue of $9.6M for the fourth quarter 2024 (Q4 2024), -22% from a year earlier and -17% from the quarter before.
Was Metagenomi Therapeutics profitable in the fourth quarter 2024?
Operating loss was $20.6M (-214.5% of revenue) and net loss $23.4M.